Ocugen, Inc. Files 8-K with Material Agreements

TL;DR

Ocugen filed an 8-K on 7/31/24 detailing material agreements and other events.

AI Summary

On July 31, 2024, Ocugen, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. The company also reported other events and filed financial statements and exhibits. This filing pertains to Ocugen, Inc., incorporated in Delaware.

Why It Matters

This 8-K filing indicates significant corporate actions and financial reporting by Ocugen, Inc., which could impact its stock price and investor outlook.

Risk Assessment

Risk Level: medium — 8-K filings often contain material information that can lead to significant stock price volatility.

Key Players & Entities

• Ocugen, Inc. (company) — Registrant
• July 31, 2024 (date) — Date of Earliest Event Reported
• Delaware (jurisdiction) — State of Incorporation
• 11 Great Valley Parkway Malvern, Pennsylvania 19355 (address) — Principal Executive Offices
• 484-328-4701 (phone_number) — Principal Executive Offices Phone Number

FAQ

Key Financial Figures

• $0.01 — nge on which registered Common Stock, $0.01 par value per share OCGN The Nasdaq
• $1.15 — Stock "), at a public offering price of $1.15 per share (the " Offering Price "). Pur
• $32.6 million — hares, are expected to be approximately $32.6 million after deducting the underwriting discou

Filing Documents

• tm2420013d3_8k.htm (8-K) — 35KB
• tm2420013d3_ex1-1.htm (EX-1.1) — 248KB
• tm2420013d3_ex5-1.htm (EX-5.1) — 9KB
• tm2420013d3_ex99-1.htm (EX-99.1) — 9KB
• tm2420013d3_ex99-2.htm (EX-99.2) — 9KB
• tm2420013d3_ex5-1img001.jpg (GRAPHIC) — 3KB
• tm2420013d3_ex99-1img002.jpg (GRAPHIC) — 21KB
• tm2420013d3_ex99-2img003.jpg (GRAPHIC) — 21KB
• 0001104659-24-084689.txt ( ) — 618KB
• ocgn-20240731.xsd (EX-101.SCH) — 3KB
• ocgn-20240731_lab.xml (EX-101.LAB) — 33KB
• ocgn-20240731_pre.xml (EX-101.PRE) — 22KB
• tm2420013d3_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On July 31, 2024, Ocugen, Inc. (the " Company ") entered into an underwriting agreement (the " Underwriting Agreement ") with Titan Partners Group LLC, a division of American Capital Partners, LLC (the " Underwriter "), pursuant to which the Company agreed to issue and sell to the Underwriter, in a public offering (the " Offering ") 30,434,783 shares of the Company's common stock, par value $0.01 per share (the " Common Stock "), at a public offering price of $1.15 per share (the " Offering Price "). Pursuant to the terms of the Underwriting Agreement, the Company granted to the Underwriter a 30-day option to purchase up to an additional 4,565,217 shares of Common Stock at the Offering Price (the " Option Shares ") at the public offering price, less underwriting discounts and commissions. The financing was led by a premier mutual fund, along with participation from leading life sciences investors. The offering is expected to close on or about August 2, 2024, subject to the satisfaction of customary closing conditions. The net proceeds to the Company from the Offering, excluding any exercise by the Underwriter of its 30-day option to purchase any of the Option Shares, are expected to be approximately $32.6 million after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the proceeds from the Offering for general corporate purposes, capital expenditures, working capital and general and administrative expenses . The Offering was made pursuant to a prospectus supplement, dated July 31, 2024 (the " Prospectus Supplement "), filed with the Securities and Exchange Commission (" SEC ") on August 1, 2024, and an accompanying base prospectus that forms a part of the Company's Registration Statement on Form S-3 (File No. 333-278774), which was previously filed with the Securities and Exchange Commission on April 18, 2024 and became eff

01. Other Events

Item 8.01. Other Events. On July 31, 2024, the Company issued a press release announcing the launch of the Offering. On July 31, 2024, the Company issued a press release announcing it had priced the Offering. Copies of the press releases are filed as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. Cautionary Note Regarding Forward Looking Statements This Current Report on Form 8-K contains forward-looking statements that involve estimates, assumptions, risks and uncertainties. Forward-looking statements include, but are not limited to, statements related to the amount of proceeds expected from the Offering, the timing and certainty of completion of the Offering. The risks and uncertainties relating to the Company and the Offering include general market conditions, the Company's ability to complete the Offering on favorable terms, or at all, as well as other risks detailed from time to time in the Company's filings with the SEC, including in its Annual Report on Form 10-K for the year ended December 31, 2023 and the Prospectus Supplement. These documents contain important factors that could cause actual results to differ from current expectations and from the forward-looking Current Report on Form 8-K and the Company undertakes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date of this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 1.1 Underwriting Agreement, dated July 31, 2024, by and between Ocugen, Inc. and Titan Partners Group LLC, a division of American Capital Partners, LLC. 5.1 Opinion of Goodwin Procter LLP. 23.1 Consent of Goodwin Procter LLP (included in Exhibit 5.1). 99.1 Launch Press Release, dated July 31, 2024. 99.2 Pricing Press Release, dated July 31, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 1, 2024 OCUGEN, INC. By: /s/ Shankar Musunuri Name: Shankar Musunuri Title: Chairman, Chief Executive Officer, & Co-Founder

View Full Filing

View this 8-K filing on SEC EDGAR